Insulin-like growth factor II overexpression in myoblasts induces phenotypic changes typical of the malignant phenotype

C. P. Minniti, D. Luan, C. O'Grady, Ronald (Ron) Rosenfeld, Y. Oh, L. J. Helman

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

The objective of this study was to examine the role of insulin-like growth factor II (IGF-II) in the pathogenesis of human rhabdomyosarcomas (RMS). We have demonstrated previously that RMS express high levels of IGF-II mRNA, secrete IGF-II peptide, and express both IGF-I and IGF-II receptors. Moreover, we showed that IGF-II functions as an autocrine growth and motility factor in RMS. Since IGF-II is expressed at high levels in fetal muscle cells and RMS are tumors thought to derive from skeletal myoblasts arrested along the normal myogenic pathway, autocrine production of IGF-II by RMS may be an etiological event in the development of this tumor. We have developed a model system which enabled us to study the effects of endogenous IGF-II overprotection in muscle myoblasts. Human cDNA for pre-prohormone IGF-II was transfected into mouse myoblasts in order to achieve high, constant expression of this growth factor, which is normally down-regulated at the end of the differentiation process. Expression of high IGF-II levels resulted in: (a) an increased proliferative rate; (b) impairment of the ability to differentiate into myoblasts; and (c) acquisition of the capability of anchorage-independent growth. No changes in the expression of IGF-I receptors were noted. We conclude that IGF-II overexpression in muscle myoblasts induces morphological and biological changes typical of the malignant phenotype and represents a fundamental event in the pathogenesis of RMS and possibly of other embryonal tumors.

Original languageEnglish (US)
Pages (from-to)263-269
Number of pages7
JournalCell Growth and Differentiation
Volume6
Issue number3
StatePublished - 1995
Externally publishedYes

Fingerprint

Insulin-Like Growth Factor II
Myoblasts
Rhabdomyosarcoma
Phenotype
Intercellular Signaling Peptides and Proteins
Skeletal Myoblasts
IGF Type 2 Receptor
Glucose-6-Phosphate Isomerase
Muscles
Neoplasms
IGF Type 1 Receptor
Insulin-Like Growth Factor I
Muscle Cells
Complementary DNA
Messenger RNA
Peptides

ASJC Scopus subject areas

  • Cell Biology
  • Molecular Biology

Cite this

Minniti, C. P., Luan, D., O'Grady, C., Rosenfeld, R. R., Oh, Y., & Helman, L. J. (1995). Insulin-like growth factor II overexpression in myoblasts induces phenotypic changes typical of the malignant phenotype. Cell Growth and Differentiation, 6(3), 263-269.

Insulin-like growth factor II overexpression in myoblasts induces phenotypic changes typical of the malignant phenotype. / Minniti, C. P.; Luan, D.; O'Grady, C.; Rosenfeld, Ronald (Ron); Oh, Y.; Helman, L. J.

In: Cell Growth and Differentiation, Vol. 6, No. 3, 1995, p. 263-269.

Research output: Contribution to journalArticle

Minniti, CP, Luan, D, O'Grady, C, Rosenfeld, RR, Oh, Y & Helman, LJ 1995, 'Insulin-like growth factor II overexpression in myoblasts induces phenotypic changes typical of the malignant phenotype', Cell Growth and Differentiation, vol. 6, no. 3, pp. 263-269.
Minniti, C. P. ; Luan, D. ; O'Grady, C. ; Rosenfeld, Ronald (Ron) ; Oh, Y. ; Helman, L. J. / Insulin-like growth factor II overexpression in myoblasts induces phenotypic changes typical of the malignant phenotype. In: Cell Growth and Differentiation. 1995 ; Vol. 6, No. 3. pp. 263-269.
@article{f35d8282b13049c3a4c762f2ecba0f1e,
title = "Insulin-like growth factor II overexpression in myoblasts induces phenotypic changes typical of the malignant phenotype",
abstract = "The objective of this study was to examine the role of insulin-like growth factor II (IGF-II) in the pathogenesis of human rhabdomyosarcomas (RMS). We have demonstrated previously that RMS express high levels of IGF-II mRNA, secrete IGF-II peptide, and express both IGF-I and IGF-II receptors. Moreover, we showed that IGF-II functions as an autocrine growth and motility factor in RMS. Since IGF-II is expressed at high levels in fetal muscle cells and RMS are tumors thought to derive from skeletal myoblasts arrested along the normal myogenic pathway, autocrine production of IGF-II by RMS may be an etiological event in the development of this tumor. We have developed a model system which enabled us to study the effects of endogenous IGF-II overprotection in muscle myoblasts. Human cDNA for pre-prohormone IGF-II was transfected into mouse myoblasts in order to achieve high, constant expression of this growth factor, which is normally down-regulated at the end of the differentiation process. Expression of high IGF-II levels resulted in: (a) an increased proliferative rate; (b) impairment of the ability to differentiate into myoblasts; and (c) acquisition of the capability of anchorage-independent growth. No changes in the expression of IGF-I receptors were noted. We conclude that IGF-II overexpression in muscle myoblasts induces morphological and biological changes typical of the malignant phenotype and represents a fundamental event in the pathogenesis of RMS and possibly of other embryonal tumors.",
author = "Minniti, {C. P.} and D. Luan and C. O'Grady and Rosenfeld, {Ronald (Ron)} and Y. Oh and Helman, {L. J.}",
year = "1995",
language = "English (US)",
volume = "6",
pages = "263--269",
journal = "Molecular Cancer Research",
issn = "1541-7786",
publisher = "American Association for Cancer Research Inc.",
number = "3",

}

TY - JOUR

T1 - Insulin-like growth factor II overexpression in myoblasts induces phenotypic changes typical of the malignant phenotype

AU - Minniti, C. P.

AU - Luan, D.

AU - O'Grady, C.

AU - Rosenfeld, Ronald (Ron)

AU - Oh, Y.

AU - Helman, L. J.

PY - 1995

Y1 - 1995

N2 - The objective of this study was to examine the role of insulin-like growth factor II (IGF-II) in the pathogenesis of human rhabdomyosarcomas (RMS). We have demonstrated previously that RMS express high levels of IGF-II mRNA, secrete IGF-II peptide, and express both IGF-I and IGF-II receptors. Moreover, we showed that IGF-II functions as an autocrine growth and motility factor in RMS. Since IGF-II is expressed at high levels in fetal muscle cells and RMS are tumors thought to derive from skeletal myoblasts arrested along the normal myogenic pathway, autocrine production of IGF-II by RMS may be an etiological event in the development of this tumor. We have developed a model system which enabled us to study the effects of endogenous IGF-II overprotection in muscle myoblasts. Human cDNA for pre-prohormone IGF-II was transfected into mouse myoblasts in order to achieve high, constant expression of this growth factor, which is normally down-regulated at the end of the differentiation process. Expression of high IGF-II levels resulted in: (a) an increased proliferative rate; (b) impairment of the ability to differentiate into myoblasts; and (c) acquisition of the capability of anchorage-independent growth. No changes in the expression of IGF-I receptors were noted. We conclude that IGF-II overexpression in muscle myoblasts induces morphological and biological changes typical of the malignant phenotype and represents a fundamental event in the pathogenesis of RMS and possibly of other embryonal tumors.

AB - The objective of this study was to examine the role of insulin-like growth factor II (IGF-II) in the pathogenesis of human rhabdomyosarcomas (RMS). We have demonstrated previously that RMS express high levels of IGF-II mRNA, secrete IGF-II peptide, and express both IGF-I and IGF-II receptors. Moreover, we showed that IGF-II functions as an autocrine growth and motility factor in RMS. Since IGF-II is expressed at high levels in fetal muscle cells and RMS are tumors thought to derive from skeletal myoblasts arrested along the normal myogenic pathway, autocrine production of IGF-II by RMS may be an etiological event in the development of this tumor. We have developed a model system which enabled us to study the effects of endogenous IGF-II overprotection in muscle myoblasts. Human cDNA for pre-prohormone IGF-II was transfected into mouse myoblasts in order to achieve high, constant expression of this growth factor, which is normally down-regulated at the end of the differentiation process. Expression of high IGF-II levels resulted in: (a) an increased proliferative rate; (b) impairment of the ability to differentiate into myoblasts; and (c) acquisition of the capability of anchorage-independent growth. No changes in the expression of IGF-I receptors were noted. We conclude that IGF-II overexpression in muscle myoblasts induces morphological and biological changes typical of the malignant phenotype and represents a fundamental event in the pathogenesis of RMS and possibly of other embryonal tumors.

UR - http://www.scopus.com/inward/record.url?scp=0028945420&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028945420&partnerID=8YFLogxK

M3 - Article

C2 - 7794794

AN - SCOPUS:0028945420

VL - 6

SP - 263

EP - 269

JO - Molecular Cancer Research

JF - Molecular Cancer Research

SN - 1541-7786

IS - 3

ER -